Home
Storia in 2 fonti
Eli Lilly acquires Engage Biologics for up to $202 million
The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome
- ·
pharmaceutical-technology.com
Eli Lilly maintains M&A streak with $202m Engage Bio buyout - Pharmaceutical Technology
Eli Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.
- ·
qz.com
Eli Lilly acquires Engage Biologics for up to $202 million
The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome